Pfizer acquires Rinat Neuroscience

New York, April 6 - Pfizer Inc. said it has agreed to acquire Rinat Neuroscience Corp., a privately held biotechnology company developing therapeutic proteins for the treatment of diseases and disorders of the central nervous system.

Terms were not disclosed.

Rinat was founded in 2001 when Genentech, Inc. granted Rinat broad licenses to its key neuroscience assets. The most advanced new drug candidate in Rinat's pipeline is RN624, a potential new treatment for acute and chronic pain that is currently entering phase 2 clinical trials. RN624 inhibits nerve growth factor which may play a role in reducing chronic pain without side effects common in similar therapies.

Rinat is also developing RN1219 for the potential treatment of Alzheimer's disease. RN1219, a humanized monoclonal antibody, has been shown to reduce amyloid plaque in pre-clinical studies. The build up of amyloid deposits in the brain contributes to the progressive death of nerve cells that occurs in Alzheimer's patients.

Rinat has additional compounds in late pre-clinical development for migraine prophylaxis and cachexia as well as discovery programs in obesity, pain, neuropathy and Parkinson's disease, Pfizer noted.

"More than one billion people around the world suffer from neurological conditions and diseases, and finding new, more effective treatments for patients is a high priority for Pfizer research and development," said John LaMattina, president, global research & development for Pfizer, in a news release.

"Rinat is a pioneer in developing protein-based therapeutics and we see tremendous potential in its research to develop new medicines, notably for the treatment of Alzheimer's disease.

"Combining Rinat's potential product portfolio with Pfizer's capabilities is a further step in our strategy to enhance Pfizer's internal research and development efforts with high-potential, externally sourced product candidates and technologies."

Pfizer is a New York-based pharmaceutical company. Rinat is based in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.